Biocon Biologics, a subsidiary of Biocon Limited, will unveil three oncology biosimilars at a US healthcare conference in January 2026. The assets include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab, as disclosed in NSE and BSE filings.
Source: Biocon Limited Press Release (NSE Exchange Filings) | Published on Jan 05, 2026
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Biocon Limited (NSE Exchange Filings), the company informed stock exchanges about a new oncology portfolio update. The disclosure was shared with the NSE and BSE on January 6, 2026.
The filing states that Biocon Biologics Ltd., a subsidiary of Biocon Limited, will unveil three oncology biosimilars. The announcement will take place at the 2026 J.P. Morgan Healthcare Conference in the United States.
The update clearly lists the names of the biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The present information regarding assets presented at the conference does not include any details about launch dates, commercial information, or time frames for these presentations.
The only information provided by the presenters is information that has already been made public through the stock exchanges.
Also Read: Titan Q3 FY26 Consumer Business Growth and Retail Expansion Data
Biocon Biologics will show off three oncology biosimilars
The news comes from a US healthcare meeting
The disclosure was made on January 6, 2026
The news was shared on NSE and BSE
Based on the filing with the exchange, the oncology biosimilars are in the biologics section. These treatments are used to treat cancer all over the world.
The three products named in the disclosure are Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The filing confirms that these assets will be presented as part of the company’s oncology portfolio update.
Biocon Biologics already has 17 oncology assets, as per the press release. These include biosimilars and other cancer therapies. The new assets will be added to this disclosed portfolio.
The communication does not include performance data. It does not provide forecasts or expectations. The update follows standard regulatory disclosure norms.
Particulars | Details |
Subsidiary Name | Biocon Biologics Ltd. |
Parent Company | Biocon Limited |
Number Of Biosimilars | Three |
Therapy Area | Oncology |
Product Names | Trastuzumab/Hyaluronidase, Nivolumab, Pembrolizumab |
Disclosure Date | January 6, 2026 |
Source | NSE And BSE Filings |
As per NSE data, Biocon Limited share price stood at ₹386.60 on January 6, 2026. The data was recorded at 15:30 PM IST.
The stock opened at ₹391.45 during the trading session. It moved to a high of ₹394.60 and a low of ₹382.95. The previous closing price was ₹391.35.
The share price information has been presented separately from the operational update. This follows exchange reporting standards for Biocon Limited and share price disclosures.
The filing also refers to the planned integration of Biocon Biologics as a wholly owned subsidiary of Biocon Limited. The update states that this integration is subject to required approvals.
The disclosure remains factual and limited in scope. It includes only information shared with stock exchanges. No assumptions or forward-looking statements have been included.
All details are sourced from official NSE and BSE filings and the enclosed press release.
Also Read: IEX Market Coupling Update with APTEL Hearing Clarification and Share Data
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading